List of cancer mortality rates in the United States
Different types of cancer can vary wildly in their prognosis. While the stage of cancer at diagnosis is most relevant to the survival of an individual patient, the type of cancer suggests an overall survival rate of the population.
The figures below are an overall reflection of mortality rates throughout the U.S. population. For example, those diagnosed with breast or prostate cancer have a much better outcome than those diagnosed with lung or stomach cancer. In most statistical records, cancers are grouped by location, although some cancers of the same location can have extremely variable survival rates depending on the type of cancer. For example, stage 1 pancreatic adenocarcinoma has a 5-year survival rate of 12%, while stage 1 pancreatic neuroendocrine tumors have a 5-year survival rate of 61%.
Age is also a factor. For seniors above 65 diagnosed with Glioblastoma, the survival rate is as low as 4%, however, for babies born with it, the survival rate can be up to 42%.
Between 2007 and 2013, the percentage of people with cancer alive at five years after diagnosis are displayed in the table below. These figures represent all deaths, whether due to cancer itself, or death from another cause in a person with cancer.
Five year survival by type
Note: This is not a complete list of cancer mortality rates as published by the NCI. These figures are at least five years old and do not reflect recent advances in medicine that have improved the detection and treatments of cancer and their outcomes. Again, these are average death rates that should not be assumed to apply to individuals, whose prognoses will vary depending on age, gender, race, general health, the swiftness of detection, type of treatment, the progression of the disease, and complicating factors. Also, survival for 5 years doesn't mean a good outcome for some conditions, most notably Myeloma, which almost always is eventually fatal, but patients can expect to live for 3-6 years with current treatments.
|Type||Five year survival rate||Ten year survival rate (If available)|
|Small intestine cancer||67.5%||63%|
|Liver and bile duct cancer||22%||17%|
|Pancreatic cancer (all types)||8.2%||2.2%|
|Pancreatic neuroendocrine tumor||61%||50%|
|Lung cancer (all types)||18.1%||7%|
|Tracheal (Windpipe) cancer||52.9%||50%|
|Bone cancer (all types)||67.7%||56%|
|Soft tissue, not otherwise specified||64.4%||62%|
|Skin cancer (excluding basal and squamous)||91.7%||90%|
|Breast cancer in situ||100%||100%A|
|Glioblastoma||3% - 42%||19% |
|Diffuse intrinsic pontine glioma (brain stem)||<1%||0%|
|Myeloma (plasma blood cell cancer)||49.9%||18%|
|Non lymphoma lymph node cancer||48%||39%|
|Leukemia, acute lymphocytic||68.2%||51%|
|Leukemia, acute myelomonocytic||24%||9%|
|Leukemia, chronic lymphocytic||83.2%||69%|
|Leukemia, chronic myeloid||66.9%||50%|
A While breast cancer in situ is not a true cancer (lacking the invasive nature of cancer), physicians often present the diagnosis of cancer to patients. In recent years, this has been controversial, as it artificially inflates the rates of breast cancer.